Biotech · Public company · South San Francisco, CA, US
Alumis Inc.
Ticker ALMS · SEC CIK 0001847367
Track this companyFree. Adds Alumis Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials133 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- ApremilastPhase 3 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Blinded EnvudeucitinibPhase 3 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- EnvudeucitinibPhase 3 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Open-Label EnvudeucitinibPhase 3 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- EnvudeucitinibPhase 2 · SLEClinicalTrials.gov · fetched Nov 12, 2026
- ESK-001Phase 2 · Uveitis Posterior Non-InfectiousClinicalTrials.gov · fetched Nov 12, 2026
- ESK-001Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- A-005Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- envudeucitinibPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- ESK-001Phase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- ESK-001Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- ESK-001Phase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Experimental drug: ESK-001Phase 1 · Safety and TolerabilityClinicalTrials.gov · fetched Nov 12, 2026
- Moxifloxacin (400 mg)Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- RabeprazolePhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamagePHASE1 · COMPLETED · started Apr 29, 2025ClinicalTrials.gov NCT06952634 · fetched Nov 12, 2026
- An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal FunctionPHASE1 · COMPLETED · started Apr 23, 2025ClinicalTrials.gov NCT06962774 · fetched Nov 12, 2026
- Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 8, 2025ClinicalTrials.gov NCT06846541 · fetched Nov 12, 2026
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001PHASE3 · COMPLETED · started Aug 20, 2024ClinicalTrials.gov NCT06588738 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisPHASE3 · COMPLETED · started Jul 25, 2024ClinicalTrials.gov NCT06586112 · fetched Nov 12, 2026
- An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001PHASE1 · COMPLETED · started Jun 21, 2024ClinicalTrials.gov NCT07378579 · fetched Nov 12, 2026
- An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005PHASE1 · COMPLETED · started Apr 22, 2024ClinicalTrials.gov NCT07442149 · fetched Nov 12, 2026
- Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 26, 2023ClinicalTrials.gov NCT05966480 · fetched Nov 12, 2026
- POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUPHASE2 · TERMINATED · started Jun 14, 2023ClinicalTrials.gov NCT05953688 · fetched Nov 12, 2026
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 17, 2023ClinicalTrials.gov NCT05739435 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisPHASE2 · COMPLETED · started Sep 27, 2022ClinicalTrials.gov NCT05600036 · fetched Nov 12, 2026
- Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsPHASE1 · COMPLETED · started May 12, 2022ClinicalTrials.gov NCT05431634 · fetched Nov 12, 2026
- Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsPHASE1 · COMPLETED · started Mar 17, 2022ClinicalTrials.gov NCT05330858 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Sep 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 9, 2026 · fetched Nov 12, 2026